Shenzhen S.E.
03:30:00 26/06/2024 am IST
5-day change
1st Jan Change
36.8
CNY
+5.29%
-0.51%
-37.56%
SyntekaBio, Inc. signed Memorandum of Understanding to acquire bioSeedin from Acrobiosystems Co.,Ltd..
SyntekaBio, Inc. (KOSDAQ:A226330) signed Memorandum of Understanding to acquire bioSeedin from Acrobiosystems Co.,Ltd. (SZSE:301080) on June 20, 2024.
SyntekaBio, Inc. signed Memorandum of Understanding to acquire bioSeedin from Acrobiosystems Co.,Ltd..
20/06
CI
Acrobiosystems Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
18/04
CI
ACROBiosystems Launches 3D Organoid Solutions, Propelling New Frontiers in Biotherapeutic Research
10/04
CI
Tranche Update on Acrobiosystems Co.,Ltd.'s Equity Buyback Plan announced on July 18, 2023.
18/01
CI
Acrobiosystems Co.,Ltd.'s Equity Buyback announced on July 18, 2023, has closed with 273,800 shares, representing 0.23% for CNY 16 million.
17/01
CI
Tranche Update on Acrobiosystems Co.,Ltd.'s Equity Buyback Plan announced on July 18, 2023.
03/01
CI
Acrobiosystems Launches Gmp Grade Dll4 Protein to Accelerate Stem Cell Manufacturing
16/11
CI
Acrobiosystems Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
29/23/29
CI
Tranche Update on Acrobiosystems Co.,Ltd.'s Equity Buyback Plan announced on July 18, 2023.
10/23/10
CI
Acrobiosystems Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
28/23/28
CI
Acrobiosystems Co.,Ltd. Approves Board Elections
04/23/04
CI
Acrobiosystems Co.,Ltd. announces an Equity Buyback for CNY 30 million worth of its shares.
17/23/17
CI
Acrobiosystems Co.,Ltd. authorizes a Buyback Plan.
17/23/17
CI
ACROBiosystems, Through ACRO Certify and Under its Aneuro Brand, Announces Launch of in Vivo Electrophysiology Solutions for Neuroscience Research with Diagnostic Biochips
09/23/09
CI
Acrobiosystems Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
25/23/25
CI
ACROBiosystems Launches New Logistics Center in Switzerland to Help Accelerate Drug Development Throughout Europe
18/22/18
CI
Acrobiosystems Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
25/22/25
CI
Certain A Shares of Acrobiosystems Co.,Ltd. are subject to a Lock-Up Agreement Ending on 19-OCT-2022.
19/22/19
CI
Shanghai Biaodu Biotech Co., Ltd. announced that it has received $3 million in funding from Baotou Hongyuan Investment Management Consultation Co., Ltd., Huaige Capital, Acrobiosystems Co.,Ltd.
23/22/23
CI
Acrobiosystems Co.,Ltd.(XSEC:301080) added to S&P Global BMI Index
19/22/19
CI
Acrobiosystems Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
29/22/29
CI
Acrobiosystems Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
22/22/22
CI
Acrobiosystems Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
14/22/14
CI
Baisi Medical Diagnostic Technology Co., Ltd. announced that it has received CNY 20 million in funding from Acrobiosystems Co.,Ltd., Beijing Juli Changxin Enterprise Management Consulting Partnership (Limited Partnership)
24/22/24
CI
Baisi Medical Diagnostic Technology Co., Ltd. announced that it expects to receive CNY 20 million in funding from Acrobiosystems Co.,Ltd., Beijing Juli Changxin Enterprise Management Consulting Partnership (Limited Partnership), and another investor
18/22/18
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Acrobiosystems Co Ltd is a China-based company specializing in providing recombinant protein and other key biological reagent products and technical services. The Company's main products are recombinant proteins and detection services, as well as kits, antibodies, fillers, culture media and other related products. The Company's main products and services are applied to research and development (R&D) and production links such as early drug discovery and verification, drug screening and optimization, development and optimization of diagnostic reagents, preclinical and clinical trials, drug production process and process control (CMC) of tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases.
More about the company
Last Close Price
36.8
CNY
Average target price
56.78
CNY
Spread / Average Target
+54.28%
Consensus
1st Jan change
Capi.
-37.56% 606M +54.61% 811B +43.79% 640B -6.33% 353B +20.62% 333B +10.44% 302B +17.87% 246B +2.49% 225B +12.75% 218B +8.61% 168B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
ACROBIOSYSTEMS CO.,LTD. 
